CliffBio
small molecule

VELSIPITY

ETRASIMOD ARGININE

Loss of exclusivityJune 2036latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameVELSIPITY
Active ingredientETRASIMOD ARGININE
StrengthEQ 2MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

Listed patents

PatentExpiresType
10676435June 2036use U-3731
10301262June 2036substance, product
11884626June 2036use U-3731
11091435June 2036substance, product
12377071January 2036use U-4255
11007175January 2036use U-3730
12156866January 2036use U-4047
8580841March 2030substance, product
9126932July 2029use U-3732

Regulatory exclusivity

CodeExpires
NCEOctober 2028

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VELSIPITY patent cliff — loss of exclusivity June 2036 | CliffBio